Key result
Buyang Huanwu decoction suppresses inflammatory markers and inhibits proliferation in angiotensin II-stimulated cardiac fibroblasts.
Why the study?
Myocardial fibrosis is a major pathological change underlying heart failure, but its underlying molecular mechanism remains elusive.
Does Buyang Huanwu decoction-containing serum inhibit fibroblast proliferation, migration, and pro-inflammatory factor expression (IL-6, IL-1β, MMP9) in an in vitro rat cardiac fibroblast model of myocardial fibrosis?
Does Buyang Huanwu decoction-containing serum inhibit fibroblast proliferation, migration, and pro-inflammatory factor expression (IL-6, IL-1β, MMP9) in an in vitro rat cardiac fibroblast model of myocardial fibrosis?
This preclinical study combines network pharmacology and in vitro assays to suggest that Buyang Huanwu decoction attenuates Angiotensin II-induced cardiac fibroblast activation and inflammatory cytokine expression (IL-6, IL-1β, MMP9) via the IL-17 pathway.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for Buyang Huanwu decoction in myocardial fibrosis; leaves open clinical translation pending human studies.
Among cardiovascular diseases, myocardial fibrosis (MF) is a major pathological change underlying heart failure and is associated with a high mortality rate. However, the molecular mechanism underlying MF has remained elusive. Buyang Huanwu decoction (BYHWD), a traditional Chinese medicine (TCM) formula for cardiovascular diseases, exhibits good anti-inflammatory and blood-activating properties. In the present study, we studied the MF inhibitory effect of BYHWD using network pharmacology and experimental validation. We used several databases to collect information on MF and related drugs and finally obtained cross-targets for BYHWD and MF. After that we got protein-protein interaction (PPI) network and performed gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses to obtain key signaling pathways for further study. After screening, interleukin (IL)-6, IL-1β, and matrix metallopeptidase 9 (MMP9) were selected for in vitro experiments, which included cell cycle studies, cell migration rate, quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and western blotting (WB). Finally, molecular docking was performed to validate the results. We found 299 common targets between BYHWD and MF. In total, 75 core targets of the PPI core network were selected for enrichment analysis, and the IL-17 signaling pathway, which is intricately linked to inflammation, was speculated to be involved. Accordingly, in vitro experiments were performed. Altogether, our findings indicated that BYHWD can affect the function of cardiac fibroblasts and reduce the expression of inflammatory factors in rats. In summary, BYHWD can inhibit MF by reducing the expression of inflammatory factors and affecting the IL-17 signaling pathway.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) studied Myocardial fibrosis (in vitro rat cardiac fibroblast model induced by Angiotensin II) (n=28). Buyang Huanwu decoction (BYHWD)-containing rat serum vs. 10% blank control rat serum (from rats given normal saline) added to Angiotensin II-induced model cells was evaluated on Expression of IL-6, IL-1β, and MMP9 (mRNA and protein) and rat cardiac fibroblast proliferation and migration (p=<0.05). Buyang Huanwu decoction-containing serum reduced IL-6, IL-1β, and MMP9 expression and inhibited S+G2 cell cycle progression in Ang II-induced rat cardiac fibroblasts.
Synapse has enriched 10 related papers. Consider them for comparative context: